I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome

Sep. 13, 2022 10:21 AM ETI-Mab (IMAB)By: Anuron Mitra, SA News Editor

Blood sample for Myelodysplastic syndrome test.

Md Babul Hosen/iStock via Getty Images

  • Chinese biotech I-Mab (NASDAQ:IMAB) on Tuesday said it got local regulatory approval to start a phase 3 trial evaluating its antibody lemzoparlimab in combination with cancer drug azacitidine for the treatment of myelodysplastic syndrome (MDS).
  • MDS is a group of cancers caused due to blood cells that are poorly formed or don't work properly.
  • The approval to start the trial follows a successful completion of an end-of-phase 2 meeting with the Center for Drug Evaluation of China's National Medical Products Administration, IMAB said in a statement.
  • The meeting was supported by results from a phase 2 trial assessing lemzoparlimab in combination with azacitidine for the treatment of patients with newly diagnosed higher-risk MS, IMAB said.
  • The company said it is on track to initiate the late-stage study as planned.
  • U.S.-listed shares of IMAB -4.8% at $5.31 in morning trading.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.